News
  • Thomas Prevot

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer 1200 627 Thomas Prevot

TORONTO, June 13, 2023— DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company’s Chief Executive Officer and member of the Board of Directors. Mr.…

read more
  • Etienne Sibille

DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging
DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging 940 788 Etienne Sibille

DAMONA raises US5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits

read more
  • Thomas Prevot

The Ontario Brain Institute invests $400,000 CAD in DAMONA
The Ontario Brain Institute invests $400,000 CAD in DAMONA 2023 774 Thomas Prevot

We are delighted to announce that the Ontario Brain Institute (OBI) is investing approximately $400,000 CAD in Damona Pharmaceuticals, to provide support to the company developing treatments for cognitive deficits in depression and other brain disorders. DAMONA’s team is excited to engage with OBI, and thank them for their support.

read more
  • Thomas Prevot

New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits
New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits 375 375 Thomas Prevot

Through a multicentered collaboration, joining experts from the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN), Yao and colleagues are presenting this new release, highlighting how depression impairs cortical inhibition and stimulus processing Find Article Cortical processing depends on finely tuned excitatory and inhibitory connections in neuronal microcircuits. Reduced inhibition by…

read more
  • Thomas Prevot

Living With Dementia – Dr. Sibille presents how his work can help (CTV Your Morning)
Living With Dementia – Dr. Sibille presents how his work can help (CTV Your Morning) 150 150 Thomas Prevot

LIVING WITH DEMENTIA – CTV Your Morning  https://www.youtube.com/watch?v=8AVa1frLbyA From CTV Your Morning On September 16th, 2021, CTV Your Morning presented a media piece about memory loss and how CAMH contributes to tackling this issue. It introduces Paul Leah, an individual that had a stroke more than 10 years ago, damaging a quarter of his brain. Paul now lives…

read more
  • Thomas Prevot

What Happens to Our Brains When We Get Depressed?
What Happens to Our Brains When We Get Depressed? 150 150 Thomas Prevot

The human brain, in all its complexity, is nearly impossible to model. Neuroscientists are trying anyway. Illustration by Jeremy Leung The WALRUS, Canadian general-interest magazine published a new piece on May 19th, 2021 about CAMH scientists working towards clarifying the impact of depression on our brain. The piece by writer Simon Lewsen, and beautifully illustrated by…

read more
  • Thomas Prevot

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype
New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype 613 472 Thomas Prevot

The paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit in brain inhibition is due do dysfunctional somatostatin (SST) cells, causing mood and cognitive symptoms in patients. Using transgenic mice in which the SST cell…

read more
  • Thomas Prevot

Alpha Cog graduates from the Creative Destructive Lab – Edition 2019-2020
Alpha Cog graduates from the Creative Destructive Lab – Edition 2019-2020 256 256 Thomas Prevot

Our team is proud of being part of the graduating ventures participating in the 2019-2020 Edition of the Creative Destruction Lab (CDL). CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Alpha Cog participated in the Health Stream, and received valuable inputs from mentors from September…

read more

CAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot

CAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot 1440 780 Etienne Sibille

On October the 18th, a sold-out crowd of nearly 300 young professionals gathered at Ricarda’s Toronto to award $10,000 as part of the 6th Annual Breakthrough Challenge, a signature event by CAMH Engage in support of mental health research. CAMH Engage is a group of young professionals in Toronto dedicated to reducing the stigma surrounding…

https://www.camh.ca/en/camh-news-and-stories/camh-engage-breakthrough-challenge-2019-awarded-to-dr-thomas-prevot

Lifting Brain Fog

Lifting Brain Fog 1920 800 Etienne Sibille

Effective treatments for cognitive dysfunction, such as declines in memory and other mental faculties often associated with depression or old age, may be within reach, according to Professor Etienne Sibille at the Centre for Addiction and Mental Health (CAMH) and the University of Toronto, Canada.

https://www.scientia.global/wp-content/uploads/Etienne_Sibille/Etienne_Sibille.pdf
  • 1
  • 2
Start Typing